What is a generic medicinal product?

The Austrian Medicinal Products Act defines what a generic medicinal product is:

  • §1 (19) "Generic medicinal product" means a medicinal product which must contain the same active substance in the same quantity and must also have the same pharmaceutical form (e.g. tablets, solution, suppositories) as the already authorised medicinal product from which it is derived (reference medicinal product, see below). It must also demonstrate the so-called bioequivalence (i.e. the substitutability of two medicinal products with the same active substance) with the reference medicinal product through appropriate studies.
  • §1 (20) "Reference medicinal product" (the originator) means a medicinal product authorised in Austria or in the European Economic Area.

When and how is a generic medicinal product approved?

This is also precisely regulated in the Austrian Medicinal Products Act. This so-called "generic authorisation" defines what pharmaceutical companies have to demonstrate:

  • § 10 Generic marketing authorisation: The applicant must be able to prove that the medicinal product is a generic of a reference medicinal product.
  • This must be demonstrated by a bioequivalence study and normally the generic medicinal product cannot be placed on the market in the EU until ten years have elapsed since the first authorisation of the reference medicinal product.

What is a bioequivalence study?

This is laid down in a guideline issued by the European Medicines Agency (EMA): a bioequivalence study is a study that compares whether the blood of the test subjects contains exactly the same amount of active substance from the generic (test product) at the same time and in the same amount as from the reference product (originator).

This study is a clinical trial within the meaning of the Medicinal Products Act (Arzneimittelgesetz). The basic assumption here is: essentially similar blood levels of the active substance and thus concentrations at the site of action guarantee essentially the same effect of efficacy and safety of the drug. The results of this study must be within certain limits. These limits are accepted throughout the EU and laid down in a guideline issued by the EMA.

Where are differences between the originator and the generic medicinal product possible?

  • In the case of excipients, if they have no influence on the action of the medicinal product.
  • The manufacturing process may be different.
  • For example, it is allowed that the generic medicinal product is a tablet and the originator is a capsule.
  • However, for each generic medicinal product, as for the originator, the complete pharmaceutical quality documentation must be submitted. In this respect, there is no difference between originator and generic product.

A generic medicinal product only receives approval,

  • if the results of the bioequivalence study are within the specified limits,
  • if the safety profile of the generic corresponds to that of the reference product,
  • if it has been proven that the excipients used and the manufacturing process have no influence on the availability of the generic medicinal product in the body,
  • if the internationally established quality standards for the performance of a bioequivalence study are met,
  • if all regulatory criteria are met (Summary of Products Characteristics, Package Leaflet, Labelling,...).

It is only when all these criteria are met that a generic medicinal product is marketed and therefore there is no cause for concern for prescribers or patients as regards the approval of generic medicinal products.


Further inquiry note